Patient-specific independent 3D GammaPlan quality assurance for Gamma Knife Perfexion radiosurgery.

One of the most important aspects of quality assurance (QA) in radiation therapy is redundancy of patient treatment dose calculation. This work is focused on the patient-specific time and 3D dose treatment plan verification for stereotactic radiosurgery using Leksell Gamma Knife Perfexion (LGK PFX). The virtual model of LGK PFX was developed in MATLAB, based on the physical dimensions provided by the manufacturer. The ring-specific linear attenuation coefficients (LAC) and output factors (OFs) reported by the manufacturer were replaced by the measurement-based collimator size-specific OFs and a single LAC = 0.0065 mm-1. Calculation depths for each LGK PFX shot were obtained by ray-tracing technique, and the dose calculation formalism was similar to the one used by GammaPlan treatment planning software versions 8 and 9. The architecture of the QA process was based on the in-house online database search of the LGK PFX database search for plan-specific information. A series of QA phantom plans was examined to verify geometric and dosimetric accuracy of the software. The accuracy of the QA process was further evaluated through evaluation of a series of patient plans. The shot time/focus point dose verification for each shot took less than 1 sec/shot with full 3D isodose verification taking about 30 sec/shot on a desktop PC. GammaPlan database access time took less than 0.05 sec. The geometric accuracy (location of the point of maximum dose) of the phantom and patient plan was dependent on the resolution of the original dose matrix and was of the order of 1 dose element. Dosimetric accuracy of the independently calculated phantom and patient point (focus) doses was within 3.5% from the GammaPlan, with the mean = 2.3% and SD= 1.1%. The process for independent pretreatment patient-specific Gamma Knife Perfexion time and dose verification was created and validated.

Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy.

OBJECTIVE: To review the current state of radiation therapy for uveal melanoma and compare particle radiation and brachytherapy. PATIENTS AND METHODS: The medical records of 156 patients treated for uveal melanoma between May 30, 2012, and March 16, 2020, were retrospectively reviewed. Treatments consisted of either radioactive iodine 125 implant (RAI) or fractionated proton radiation (proton beam therapy [PBT]). Baseline characteristics were compared using a Wilcoxon rank sum test or χ2 test. Outcomes were compared using Cox proportional hazards regression models or logistic regression models. RESULTS: The median length of follow-up after treatment was 2.7 years (range, 0.5 to 9.0 years). Patients who underwent treatment with RAI were older (median age, 67 vs 59 years; P<.001) and had a lower tumor classification (American Joint Commission on Cancer; P=.001) compared with those who underwent PBT. There was no significant difference between RAI and PBT in the outcomes of liver metastases, death, enucleation, tearing, vision loss, retinal detachment, tumor thickness, conjunctivitis, optic neuropathy, iris neovascularization, or neovascular glaucoma (all P>.05). Patients who underwent RAI treatment had significantly higher risk of diplopia (P<.001), cataract progression (P<.001), and maculopathy (P=.03) compared with those who received PBT. Patients who underwent RAI were at higher risk of eyelash loss (P=.006) compared with the PBT group. CONCLUSION: Treatment with PBT and RAI has similar efficacy; however, there are differences in the adverse outcomes associated with these 2 modalities.

Planning tools for modulated electron radiotherapy.

PURPOSE: To develop tools to plan modulated electron radiotherapy (MERT) and to compare the MERT plans to conventional or intensity modulated radiotherapy (IMRT) treatment plans. METHODS: Monte Carlo dose calculations of electron fields shaped with the inherent photon multileaf collimators (MLCs) were investigated in this study. Treatment plans for four postmastectomy breast cancer patients were generated using MERT. The distances from the patient skin surfaces to the distal planning target volume surfaces were computed along the beam axis direction to determine the physical depth. Electron beam energies were selected to provide target coverage at these depths and energy bins were generated. A custom built MERT treatment planning graphical user interface (MERTgui) was used to shape the electron bins into deliverable electron segments. Monte Carlo dose distribution simulations were performed using the MLC-defined segments generated from the MERTgui. A custom built superposition gui was used to combine doses for each segment using relative weights and final MERT treatment plans were compared to the conventional or IMRT treatment plans. In addition, a demonstration of combined MERT and IMRT treatment plans was performed. RESULTS: The MERT treatment plans provided acceptable target organ coverage in all cases. Relative to 3D conventional or IMRT treatment plans, the MERT plans predicted lower heart doses in all cases; average of the heart D20 of all plans was reduced from 14.1 to 3.3 Gy. The contralateral breast and contralateral lung doses decreased substantially with MERT planning compared to IMRT (on average, contralateral breast heart D20 was reduced from 8.7 to 0.7 Gy and contralateral lung D20 was reduced from 8.4 to 1.2 Gy with MERT). Ipsilateral lung D20 was lower with MERT than with the conventional plans (44.6 vs 29.2 Gy with MERT), but greater when compared against IMRT treatment plans (25.4 vs 28.9 Gy with MERT). A MERT and IMRT combination plan was generated to benefit from the complementary advantages of MERT and IMRT, resulting in satisfactory target coverage and reduced organ at risk doses. CONCLUSIONS: MERT tools can facilitate treatment planning and provide plans for treatment of shallow targets such as the postmastectomy chest wall.

Delivery of modulated electron beams with conventional photon multi-leaf collimators.

Electron beam radiotherapy is an accepted method to treat shallow tumors. However, modulation of electrons to customize dose distributions has not readily been achieved. Studies of bolus and tertiary collimation systems have been met with limitations. We pursue the use of photon multi-leaf collimators (MLC) for modulated electron radiotherapy (MERT) to achieve customized distributions for potential clinical use. As commercial planning systems do not support the use of MLC with electrons, planning was conducted using Monte Carlo calculations. Segmented and dynamic modulated delivery of multiple electron segments was configured, calculated and delivered for validation. Delivery of electrons with segmented or dynamic leaf motion was conducted. A phantom possessing an idealized stepped target was planned and optimized with subsequent validation by measurements. Finally, clinical treatment plans were conducted for post-mastectomy and cutaneous lymphoma of the scalp using forward optimization techniques. Comparison of calculations and measurements was successful with agreement of +/-2%/2 mm for the energies, segment sizes, depths tested for delivered segments for the dynamic and segmented delivery. Clinical treatment plans performed provided optimal dose coverage of the target while sparing distal organs at risk. Execution of plans using an anthropomorphic phantom to ensure safe and efficient delivery was conducted. Our study validates that MERT is not only possible using the photon MLC, but the efficient and safe delivery inherent with the dynamic delivery provides an ideal technique for shallow tumor treatment.

ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer.

PURPOSE: Using planning target volume (PTV) to account for setup uncertainties in stereotactic body radiation therapy (SBRT) of lung cancer has been questioned because a significant portion of the PTV contains low-density lung tissue. The purpose of this study is to (1) investigate the feasibility of using robust optimization to account for setup uncertainties in volumetric modulated arc therapy plan for lung SBRT and (2) evaluate the potential normal tissue-sparing benefit of a robust optimized plan compared with a conventional PTV-based optimized plan. METHODS AND MATERIALS: The study was conducted with both phantom and patient cases. For each patient or phantom, 2 SBRT lung volumetric modulated arc therapy plans were generated, including an optimized plan based on the PTV (PTV-based plan) with a 5-mm internal target volume (ITV)-to-PTV margin and a second plan based on robust optimization of ITV (ITV-based plan) with ±5-mm setup uncertainties. The target coverage was evaluated on ITV D99 in 15 scenarios that simulated a 5-mm setup error. Dose-volume information on normal lung tissue, intermediate-to-high dose spillage, and integral dose was evaluated. RESULTS: Compared with PTV-based plans, ITV-based robust optimized plans resulted in lower normal lung tissue dose, lower intermediate-to-high dose spillage to the body, and lower integral dose, while preserving the dose coverage under setup error scenarios for both phantom and patient cases. CONCLUSIONS: Using ITV-based robust optimization, we have shown that accounting for setup uncertainty in SBRT planning is feasible. Further clinical studies are warranted to confirm the clinical effectiveness of this novel approach.

MLC quality assurance using EPID: a fitting technique with subpixel precision.

Amorphous silicon based electronic portal imaging devices (EPIDs) have been shown to be a good alternative to radiographic film for routine quality assurance (QA) of multileaf collimator (MLC) positioning accuracy. In this work, we present a method of acquiring an EPID image of a traditional strip-test image using analytical fits of the interleaf and leaf abutment image signatures. After exposure, the EPID image pixel values are divided by an open field image to remove EPID response and radiation field variations. Profiles acquired in the direction orthogonal to the leaf motion exhibit small peaks caused by interleaf leakage. Gaussian profiles are fitted to the interleaf leakage peaks, the results of which are, using multiobjective optimization, used to calculate the image rotational angle with respect to the collimator axis of rotation. The relative angle is used to rotate the image to align the MLC leaf travel to the image pixel axes. The leaf abutments also present peaks that are fitted by heuristic functions, in this case modified Lorentzian functions. The parameters of the Lorentzian functions are used to parameterize the leaf gap width and positions. By imaging a set of MLC fields with varying gaps forming symmetric and asymmetric abutments, calibration curves with regard to relative peak height (RPH) versus nominal gap width are obtained. Based on this calibration data, the individual leaf positions are calculated to compare with the nominal programmed positions. The results demonstrate that the collimator rotation angle can be determined as accurate as 0.01 degrees. A change in MLC gap width of 0.2 mm leads to a change in RPH of about 10%. For asymmetrically produced gaps, a 0.2 mm MLC leaf gap width change causes 0.2 pixel peak position change. Subpixel resolution is obtained by using a parameterized fit of the relatively large abutment peaks. By contrast, for symmetrical gap changes, the peak position remains unchanged with a standard deviation of 0.05 pixels, or 0.026 mm. A trial run of 36 test images, each with gap widths varying from 0.4 to 1.4 mm, were used to analyze 8640 abutments. The leaf position variations were detected with a precision of 0.1 mm at a 95% confidence level, with a mean of 0.04 mm and a standard deviation of 0.03 mm. The proposed method is robust and minimizes the effect of image noise and pixel size and may help physicists to establish reliable and reasonable action levels in routine MLC QA.

Linac mechanic QA using a cylindrical phantom.

Precise mechanical operation of a linear accelerator (linac) is critical for accurate radiation therapy dose delivery. Quantitative procedures for linac mechanical quality assurance (QA) used in the standard of care are time consuming and therefore conducted on a relatively infrequent basis. We present a method for evaluating the mechanical performance of a linac based on a series of projection portal images of a prototype cylindrical phantom with embedded radiopaque fiducial markers. The marker autodetection process included modeling imager response to the radiation beam where the projected cylinder attenuation yielded a non-uniform image background. The linac mechanical characteristics were estimated based on nonlinear multi-objective optimization of the projected marker locations. The estimated geometry parameters for the tested commercial model were gantry angle deviation 0.075 +/- 0.076 degrees (1 SD), gantry sag 0.026 +/- 0.02 degrees , source-to-axis distance SAD 998.3 +/- 1.7 mm, source-to-detector distance SDD 1493 +/- 5.0 mm, couch vertical motion 0.6 +/- 0.45 mm, couch rotation 0.154 +/- 0.1 degrees and average linac rotation center (1.02, -0.27, -0.37) +/- (0.36,0.333,1.20) mm relative to the laser intersection. The imager shift was [-0.44, 2.6] +/- [0.20, 1.1] mm and the imager orientation was in-plane rotation 0.05 +/- 0.03 degrees , roll -0.14 +/- 0.09 degrees and pitch -0.9 +/- 0.604 degrees . The performance of this procedure concerning marker detection and optimization was examined by comparing the detected set of marker coordinates to its back-calculated counterpart for three subgroups of markers: central, wall and intermediate relative to the center of the phantom. The maximum difference was less than 0.25 mm with a mean of 0.146 mm and a standard deviation of 0.07 mm. The clinical use of this automated procedure will allow more efficient, more thorough, and more frequent mechanical linac QA.

Improving the therapeutic ratio by using proton therapy in patients with stage I or II seminoma.

OBJECTIVES: The goal of the present study was to evaluate possible dosimetric advantages of proton therapy (PT) compared with 3-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) in the treatment of patients with stage I and II seminoma. METHODS: Two representative patients (1 with left-sided and 1 with right-sided seminoma) underwent treatment planning for stage I seminoma (paraaortic lymph nodes alone) with 3DCRT (PA3d), IMRT (PAimrt) double-scatter protons (PAPds), and uniform-scanning protons (PAPus) and for stage II seminoma (paraaortics lymph nodes and iliac nodes) with 3DCRT (PI3d) , IMRT (PIimrt) double-scatter protons (PIPds), and uniform-scanning protons (PIPus). The doses to the organs at risk were compared for photons and protons. RESULTS: For stage I seminoma, PT reduced the mean dose to the stomach, ipsilateral kidney, pancreas, bowel space, small bowel, and colon compared with 3DCRT and IMRT. For stage II seminoma, PT reduced the mean dose to the same organs as in stage I seminoma with additional reductions in mean dose to the bladder and rectum compared with 3DCRT and IMRT. Uniform-scanning protons further reduced the dose to the organs at risk compared with double-scatter protons. CONCLUSIONS: PT may offer an improvement in the therapeutic ratio in patients with seminoma by reducing the dose to normal tissue. This improvement may translate into lower risks of acute gastrointestinal side effects, infertility, and secondary malignancies, which should be explored in a prospective study.

Effect of liquid embolic agents on Gamma Knife surgery dosimetry for arteriovenous malformations. Clinical article.

OBJECT: The effectiveness of Gamma Knife stereotactic surgery to obliterate brain arteriovenous malformations (AVMs) may be diminished by the preoperative adjunctive use of endovascular liquid embolic agents. The purpose of the present investigation was to determine if commercially available liquid embolic agents reduce the radiation dose to the target because of attenuation of the (60)Co beam. METHODS: The apparent linear attenuation coefficients for 120- to 140-keV radiographs in embolized regions were retrieved from CT scans for several patients with AVMs who had undergone embolization procedures with liquid embolic agents to reduce nidal volumes. Based on these coefficients and a virtual model of Gamma Knife surgery (GKS) with basic ray tracing, the authors obtained the path lengths and densities of the embolized regions. The attenuation of (60)Co beams was then calculated for various sizes and positions of embolized AVM regions and for the number of beams used for treatment. Published experiments for several high-atomic-number materials were used to estimate the effective (60)Co beam attenuation coefficients for the N-butyl cyanoacrylate (NBCA, suspended in ethiodized oil) and ethylene vinyl alcohol copolymer (EVOH, with suspended micronized tantalum powder, Onyx) used in the AVM embolizations. Dose reductions during GKS were calculated for a theoretical model based on the CT-documented apparent linear attenuation coefficients and for the (60)Co energy attenuation coefficient. Dose measurements were obtained in a phantom study with EVOH for comparison with the estimates generated from the two attenuation coefficients. RESULTS: Based on CT (keV) apparent attenuation coefficients, the authors' theoretical model predicted that the cumulative effect of either of the embolic agents decreased the number of kilovoltage photons in an embolized nidus by -8% to -15% because of the increased atomic number and density of NBCA and Onyx. However, in using the effective attenuation coefficient for the (60)Co energies as is used in GKS, the authors' theoretical model yielded only a 0.2% dose reduction per beam and a < 0.01%-0.2% dose reduction in total. These theoretical results were validated by measurements in a head phantom containing Onyx. CONCLUSIONS: Dose reduction due to attenuation of the (60)Co beam by the AVM embolization material was negligible for both NBCA and EVOH because of the high-energy (60)Co beam.

Helical tomotherapy planning for left-sided breast cancer patients with positive lymph nodes: comparison to conventional multiport breast technique.

PURPOSE: To evaluate the feasibility of using helical tomotherapy for locally advanced left-sided breast cancer. METHODS AND MATERIALS: Treatment plans were generated for 10 left-sided breast cancer patients with positive lymph nodes comparing a multiport breast (three-dimensional) technique with the tomotherapy treatment planning system. The planning target volumes, including the chest wall/breast, supraclavicular, axillary, and internal mammary lymph nodes, were contoured. The treatment plans were generated on the tomotherapy treatment planning system to deliver 50.4 Gy to the planning target volume. To spare the contralateral tissues, directional blocking was applied to the right breast and right lung. The optimization goals were to protect the lungs, heart, and right breast. RESULTS: The tomotherapy plans increased the minimal dose to the planning target volume (minimal dose received by 99% of target volume = 46.2 +/- 1.3 Gy vs. 27.9 +/- 17.1 Gy) while improving the dose homogeneity (dose difference between the minimal dose received by 5% and 95% of the planning target volume = 7.5 +/- 1.8 Gy vs. 37.5 +/- 26.9 Gy). The mean percentage of the left lung volume receiving >or=20 Gy in the tomotherapy plans decreased from 32.6% +/- 4.1% to 17.6% +/- 3.5%, while restricting the right-lung mean dose to <5 Gy. However, the mean percentage of volume receiving >or=5 Gy for the total lung increased from 25.2% +/- 4.2% for the three-dimensional technique to 46.9% +/- 8.4% for the tomotherapy plan. The mean volume receiving >or=35 Gy for the heart decreased from 5.6% +/- 4.8% to 2.2% +/- 1.5% in the tomotherapy plans. However, the mean heart dose for tomotherapy delivery increased from 7.5 +/- 3.4 Gy to 12.2 +/- 1.8 Gy. CONCLUSION: The tomotherapy plans provided better dose conformity and homogeneity than did the three-dimensional plans for treatment of left-sided breast tumors with regional lymph node involvement, while allowing greater sparing of the heart and left lung from doses associated with increased complications.